ClinicalTrials.gov
public full text
Public Domain
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab#838099
- Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema#844135
- Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma#899258
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)#1127463
- Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)#1113642
Record · ID 830510
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive